The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies

References

• QuigleyHANumber of people with glaucoma worldwideBr J Ophthalmol19968053893938695555
   PubMed Web of Science ®Google Scholar
• TielschJMSommerAKatzJRoyallRMQuigleyHAJavittJRacial variations in the prevalence of primary open-angle glaucoma: the Baltimore Eye SurveyJAMA199126633693742056646
   PubMed Web of Science ®Google Scholar
• HeijlALeskeMCBengtssonBReduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma TrialArch Ophthalmol2002120101268127912365904
   PubMed Web of Science ®Google Scholar
• KassMAHeuerDKHigginbothamEJThe Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucomaArch Ophthalmol2002120670171312049574
   PubMed Web of Science ®Google Scholar
• EdererFGaasterlandDADallyLGThe Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race: 10-year resultsOphthalmology2004111465166415051195
   PubMed Web of Science ®Google Scholar
• LeeDAHigginbothamEJGlaucoma and its treatment: a reviewAm J Health Syst Pharm200562769169915790795
   PubMed Web of Science ®Google Scholar
• TorisCBPharmacotherapies for glaucomaCurr Mol Med201010982484021091423
   PubMed Web of Science ®Google Scholar
• HigginbothamEJHansenJDavisEJWaltJGGuckianAGlaucoma medication persistence with a fixed combination versus multiple bottlesCurr Med Res Opin2009252543254719731993
   PubMed Web of Science ®Google Scholar
• FechtnerRDRealiniTFixed combinations of topical glaucoma medicationsCurr Opin Ophthalmol200415213213515021225
   PubMedGoogle Scholar
• PiltzJGrossRShinDHContralateral effect of topical beta-adrenergic antagonists in initial one-eyed trials in the ocular hypertension treatment studyAm J Ophthalmol2000130444145311024416
   PubMed Web of Science ®Google Scholar
• SherwoodMBCravenERChouCTwice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trialArch Ophthalmol200612491230123816966616
   PubMedGoogle Scholar
• StewartWCStewartJANelsonLAKruftBPhysician attitudes regarding prostaglandin treatment for glaucoma in the United States and EuropeEur J Ophthalmol20081819920418320511
   PubMed Web of Science ®Google Scholar
• StewartWCKonstasAGPfeifferNPatient and ophthalmologist attitudes concerning compliance and dosing in glaucoma treatmentJ Ocul Pharmacol Ther20042046146915684806
   PubMed Web of Science ®Google Scholar
• TorisCBGabeltBTKaufmanPLUpdate on the mechanism of action of topical prostaglandins for intraocular pressure reductionSurv Ophthalmol200853Suppl 1S107S12019038618
   PubMed Web of Science ®Google Scholar
• LiangYWoodwardDFGuzmanVMIdentification and pharmacological characterization of the prostaglandin FP receptor and FP receptor variant complexesBr J Pharmacol20081541079109318587449
   PubMed Web of Science ®Google Scholar
• ParrishRKPalmbergPSheuWPXLT Study GroupA comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter studyAm J Ophthalmol2003135568870312719078
   PubMed Web of Science ®Google Scholar
• ZimmermanTJHahnSRGelbLTanHKimEEThe impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistenceJ Ocul Pharmacol Ther200925214515219284321
   PubMed Web of Science ®Google Scholar
• KatzLJCohenJSBatoosinghALFelixCShuVSchiffmanRMTwelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertensionAm J Ophthalmol20101494661671.e120346780
   PubMed Web of Science ®Google Scholar
• ChengJWLiYWeiRLSystematic review of intraocular pressure-lowering effects of adjunctive medications added to latanoprostOphthalmic Res20094229910519546601
   PubMed Web of Science ®Google Scholar
• AptelFDenisPBalancing efficacy and tolerability of prostaglandin analogues and prostaglandin-timolol fixed combinations in primary open-angle glaucomaCurr Med Res Opin201127101949195821878000
   PubMed Web of Science ®Google Scholar
• HigginbothamEJFeldmanRStilesMDubinerHFixed Combination Investigative GroupLatanoprost and timolol combination therapy vs monotherapy: one-year randomized trialArch Ophthalmol2002120791592212096962
   PubMed Web of Science ®Google Scholar
• BrandtJDCantorLBKatzLJBimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertensionJ Glaucoma20081721121618414107
   PubMed Web of Science ®Google Scholar
• LewisRAGrossRLSallKNThe safety and efficacy of bimatoprost/timolol fixed combination: a 1-year double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertensionJ Glaucoma201019642442619855289
   PubMed Web of Science ®Google Scholar
• KonstasAGHollóGMikropoulosDTwenty-four-hour intraocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in exfoliative glaucomaBr J Ophthalmol201094220921319825835
   PubMed Web of Science ®Google Scholar
• KatsanosADastiridouAIFanariotisMKotoulaMTsironiEEBimatoprost and bimatoprost/timolol fixed combination in patients with open-angle glaucoma and ocular hypertensionJ Ocul Pharmacol Ther2011271677121214361
   PubMed Web of Science ®Google Scholar
• ParanhosAMendonçaMSilvaMJHyperemia reduction after administration of a fixed combination of bimatoprost and timolol maleate to patients on prostaglandin or prostamide monotherapyJ Ocul Pharmacol Ther20102661161521029020
   PubMed Web of Science ®Google Scholar
• BarnebeyHSOrengo-NaniaSFlowersBEThe safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solutionAm J Ophthalmol200514011715990081
   PubMed Web of Science ®Google Scholar
• QuarantaLBiagioliERivaIProstaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysisJ Ocul Pharmacol Ther20132938238923231442
   PubMed Web of Science ®Google Scholar
• LealBCMedeirosFAMedeirosFWSantoRMSusannaRJrConjunctival hyperemia associated with bimatoprost use: a histopathologic studyAm J Ophthalmol2004138231031315289152
   PubMed Web of Science ®Google Scholar
• ChenJDinhTWoodwardDFBimatoprost: mechanism of ocular surface hyperemia associated with topical therapyCardiovasc Drug Rev200523323124616252016
   PubMed Web of Science ®Google Scholar
• BeckerBDecrease in intraocular pressure in man by a carbonic anhydrase inhibitor, diamox; a preliminary reportAm J Ophthalmol1954371131513114318
   PubMed Web of Science ®Google Scholar
• SugrueMFPharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitorsProg Retin Eye Res20001918711210614682
   PubMed Web of Science ®Google Scholar
• NebbiosoMEvangelistaMLibrandoADi BlasioDPescosolidoNFixed topical combinations in glaucomatous patients and ocular discomfortExpert Opin Pharmacother2012131829183522770575
   PubMed Web of Science ®Google Scholar
• BoyleJEGhoshKGieserDKAdamsonsIAA randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study GroupOphthalmology199810510194519519787368
   PubMed Web of Science ®Google Scholar
• ClineschmidtCMWilliamsRDSnyderEAdamsonsIAA randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol Combination Study GroupOphthalmology199810510195219599787369
   PubMed Web of Science ®Google Scholar
• KonstasAGQuarantaLYanDBTwenty-four hour efficacy with the dorzolamide/timolol-fixed combination compared with the brimonidine/timolol-fixed combination in primary open-angle glaucomaEye (Lond)201226808721960068
   PubMed Web of Science ®Google Scholar
• RobinALThe role of apraclonidine hydrochloride in laser therapy for glaucomaTrans Am Ophthalmol Soc1989877297612562547
   PubMedGoogle Scholar
• ButlerPMannschreckMLinSHwangIAlvaradoJClinical experience with the long-term use of 1% apraclonidine: Incidence of allergic reactionsArch Ophthalmol19951132932967887842
   PubMed Web of Science ®Google Scholar
• BarnebeyHSRobinALZimmermanTJThe efficacy of brimonidine in decreasing elevations in intraocular pressure after laser trabeculoplastyOphthalmology19931007108310888100625
   PubMed Web of Science ®Google Scholar
• TorisCBGleasonMLCamrasCBYablonskiMEEffects of brimonidine on aqueous humor dynamics in human eyesArch Ophthalmol199511312151415177487618
   PubMedGoogle Scholar
• TorisCBCamrasCBYablonskiMEAcute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patientsAm J Ophthalmol199912881410482088
   PubMed Web of Science ®Google Scholar
• MotolkoMAComparison of allergy rates in glaucoma patients receiving brimonidine 0.2% monotherapy versus fixed-combination brimonidine 0.2%-timolol 0.5% therapyCurr Med Res Opin20082492663266718691444
   PubMed Web of Science ®Google Scholar
• OsborneSAMontgomeryDMMorrisDMcKayICAlphagan allergy may increase the propensity for multiple eye-drop allergyEye (Lond)20051912913715254495
   PubMed Web of Science ®Google Scholar
• AlvaradoJAMurphyCGFranse-CarmanLChenJUnderwoodJLEffect of beta-adrenergic agonists on paracellular width and fluid flow across outflow pathway cellsInvest Ophthalmol Vis Sci19983910181318229727404
   PubMed Web of Science ®Google Scholar
• SchumanJSKatzGJLewisRAEfficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertensionAm J Ophthalmol2005140224225016086946
   PubMed Web of Science ®Google Scholar
• HughesBABacharachJCravenERA three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertensionJ Glaucoma200514539239916148589
   PubMed Web of Science ®Google Scholar
• HommerAGanfort Investigators Group IA double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertensionEur J Ophthalmol2007171536217294383
   PubMed Web of Science ®Google Scholar